Crossmark

Compound staphylococcal lysostaphin for oral mucositis prophylaxis in hematopoietic stem cell transplantation recipients: a non-inferiority randomized trial

Crossref DOI link: https://doi.org/10.1038/s41416-025-03251-7

Published Online: 2025-11-01

Published Print: 2026-01-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Xiaoyu https://orcid.org/0000-0003-4788-6139
Pan, Zhengwen

Zhou, Weiwei

Zhang, Jianli

Xu, Liwei

Ding, Shuyi

Zeng, Liying

Huang, Yini

Fang, Zhenzhen

Pang, Weilin
License Information

Text and Data Mining valid from 2025-11-01

Version of Record valid from 2025-11-01
More Information

Article History

Received: 5 April 2025

Revised: 22 September 2025

Accepted: 23 October 2025

First Online: 1 November 2025

Competing interests

: The authors declare no competing interests.

: All participants voluntarily joined the study and provided informed consent. The study was approved by the ethics committee (Approval No. [2019]IIT1114) and registered at clinicaltrials.gov (NCT06791746).

Document is current

Any future updates will be listed below